Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced a partnership with TARA Mind, in coordination with Veterans Exploring Treatment Solutions (VETS), to support recruitment for its PARADIGM HLP003 Phase 3 clinical program targeting major depressive disorder, while also expanding mental health awareness within the veteran community. The collaboration utilizes the networks of TARA Mind and VETS to enhance veteran engagement, aligning with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, as Helus advances its FDA Breakthrough Therapy-designated HLP003 program and broader pipeline of novel serotonergic agonists addressing unmet mental health needs.

Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. The company's NSAs aim to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder, and the company maintains an extensive research portfolio of investigational NSAs.

The partnership with TARA Mind and VETS is expected to facilitate recruitment by connecting with veterans who may benefit from the PARADIGM trial. This initiative underscores Helus Pharma's commitment to addressing mental health challenges in the veteran population, a group disproportionately affected by major depressive disorder. The executive order referenced in the announcement highlights the federal priority on accelerating treatments for serious mental illness, providing a supportive policy backdrop for the trial.

Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.